Table 4.
Protective effects of the rIFNα-2b nasal spray against viral respiratory infections (per protocol analysis).
| Viruses | EER (%) | CER (%) | RR (95% CI) | ARR (%) (95% CI) | RRR (95% CI) | NNT (95% CI) |
|---|---|---|---|---|---|---|
| ADV | 3.1 | 7.2 | 0.406 (0.165–0.999) | 4.1 (0.2–8.6) | 0.594 (0.001–0.835) | 24 (12.1–446.2) |
| RSV | 0.8 | 2.8 | 0.279 (0.057–1.356) | 2.0 (−0.3 to 4.3) | 0.721 (−0.356 to 0.943) | 50 (−313.6 to 23.1) |
| Flu-A | 6.4 | 22.6 | 0.236 (0.153–0.363) | 16.1 (11.7–20.6) | 0.764 (0.637–0.847) | 7 (4.9–8.6) |
| Flu-B | 4.3 | 15.8 | 0.238 (0.164–0.388) | 11.5 (7.9–15.2) | 0.762 (0.612–0.854) | 9 (6.6–12.6) |
| PIV1-3 | 4.1 | 15.9 | 0.226 (0.139–0.368) | 11.79 (8.3–15.3) | 0.774 (0.632–0.861) | 9 (6.5–12.1) |
EER: experimental event rate; CER: control event rate; RR: relative risk; ARR: absolute risk reduction; RRR: relative risk reduction (equal to protective rate); NNT: number needed to treat.